Abstract:BackgroundTransarterial chemoembolisation (TACE) is still widely used to treat patients with advanced hepatocellular carcinoma who have no access to sorafenib in Asia. However, the indication of TACE for these patients has yet to be established. We established an objective point score to guide this decision in patients with advanced-stage hepatocellular carcinoma.MethodsWe developed a scoring system (MCCT score) based on preoperative data from a cohort of 422 patients receiving TACE as the first treatment for advanced hepatocellular carcinoma from 2006 to 2013 at Sun Yat-sen University Cancer Center, Guangzhou, China. Factors determining survival were analysed by univariate and multivariate analysis and Cox proportional hazard regression models. The scoring system was retrospectively validated in an external cohort from other two institutions (Dongguan People's Hospital and the Kaiping Central Hospital; n=237). The prognostic predictive power was compared with six different staging systems: tumour node metastasis (TNM), 7th edition; Cancer of the Liver Italian Program (CLIP); Chinese University Prognostic Index (CUPI); Okuda, Japan Integrated Staging (JIS); and Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire (GRETCH). The retrospective study was approved by the institutional review board; written informed consent was obtained from each patient.FindingsThe presence of macroscopic vascular invasion (M), Child-Pugh class B (C), C-reactive protein values (C) higher than 10 mg/L, and tumour size (T) larger than 7 cm were independent negative prognostic factors for survival and were used to create the MCCT score. The patients were divided into risk groups on the basis of their MCCT scores (low risk for ≤2 points, intermediate risk for 3–4 points, and high risk for five points). The median overall survival times were 14·4 months (95% CI 10·7–18·1) for the low-risk group, 6·8 months (6·0–7·6) of the intermediate-risk group, and 3·2 months (1·7–4·7) for the high-risk group (p<0·0001). The discriminative ability, as determined by the area under the curve (AUC) at 6 and 12 months (AUCs 0·692 at 6 months and 0·702 at 12 months) seemed to be greater than the ability of the six other hepatocellular carcinoma staging systems (AUCs range 0·501 to 0·633). The findings were supported by the external validation cohort.InterpretationThe MCCT scoring system is more accurate than the six other scoring systems in selecting patients with advanced hepatocellular carcinoma for TACE. For patients with advanced hepatocellular carcinoma with no access to sorafenib, TACE may be a valuable alternative in selecting patients (MCCT score ≤2).FundingThis study was supported by grants from the National Natural Science Foundation of China (81172037/H1606, 81272639, and 81572385), Guangdong province science and technology project of China (2013B021800159), and the Fundamental Research Funds for the Central Universities of China (13ykzd24).

Validation of the ALBI-TAE model and comparison of seven scoring systems for predicting survival outcome in patients with intermediate‐stage hepatocellular carcinoma undergoing chemoembolization

Evaluation of models to predict prognosis in patients with advanced hepatocellular carcinoma treated with TACE combined with apatinib

Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach

Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization.

A refined prediction model for survival in hepatocellular carcinoma patients treated with transarterial chemoembolization

Applicability of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma

A Novel Risk Score (MCCT) to Guide Decision for Treatment of Advanced Hepatocellular Carcinoma with Transarterial Chemoembolisation: a Derivation and Validation Study

Prognostic Evaluation for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus Patients Treated with Transarterial Chemoembolization Plus Molecular Targeted Therapies—Development and Validation of the ABPS Score

Evaluation of different scoring systems for repeating Transarterial Chemoembolization in Egyptian patients with Hepatocellular Carcinoma

Development and validation of an imaging and clinical scoring system to predict early mortality in spontaneous ruptured hepatocellular carcinoma treated with transarterial embolization

Development and validation of survival prediction models for patients with hepatocellular carcinoma treated with transcatheter arterial chemoembolization plus tyrosine kinase inhibitors

A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer

Prognostic Performance of the China Liver Cancer Staging System in Hepatocellular Carcinoma Following Transarterial Chemoembolization.

Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study

Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion

Development and Validation of a Risk Prediction Algorithm for Evaluating the Efficacy of Postoperative Adjuvant TACE Therapy for Hepatocellular Carcinoma

A New Prediction Model for Prognosis of Patients with Intermediate-Stage HCC after Conventional Transarterial Chemoembolization: an Internally Validated Study.

Validation of modified albumin-bilirubin-TNM score as a prognostic model to evaluate patients with hepatocellular carcinoma

Postsurgical Treatment With Adjuvant Transarterial Chemoembolization In Patients With Hepatitis B-Related Hepatocellular Carcinoma A Strobe-Compliant Article

Prognostic Value of Myosteatosis and Albumin–Bilirubin Grade for Survival in Hepatocellular Carcinoma Post Chemoembolization

An Integrated Liver Function, Systemic Inflammation, and Tumor Characteristic Score Predicts Prognosis in Hepatocellular Carcinoma After Curative Resection